Teva Pharmaceutical Industries (TEVA) Enterprise Value: 2009-2025
Historic Enterprise Value for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $21.0 billion.
- Teva Pharmaceutical Industries' Enterprise Value rose 20.43% to $21.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 billion, marking a year-over-year increase of 54.53%. This contributed to the annual value of $22.0 billion for FY2024, which is 141.98% up from last year.
- According to the latest figures from Q3 2025, Teva Pharmaceutical Industries' Enterprise Value is $21.0 billion, which was up 22.87% from $17.1 billion recorded in Q2 2025.
- Over the past 5 years, Teva Pharmaceutical Industries' Enterprise Value peaked at $22.0 billion during Q4 2024, and registered a low of $6.4 billion during Q2 2023.
- Its 3-year average for Enterprise Value is $14.2 billion, with a median of $15.7 billion in 2025.
- As far as peak fluctuations go, Teva Pharmaceutical Industries' Enterprise Value decreased by 25.16% in 2022, and later soared by 154.55% in 2024.
- Over the past 5 years, Teva Pharmaceutical Industries' Enterprise Value (Quarterly) stood at $7.6 billion in 2021, then grew by 6.36% to $8.1 billion in 2022, then increased by 12.00% to $9.1 billion in 2023, then spiked by 141.98% to $22.0 billion in 2024, then climbed by 20.43% to $21.0 billion in 2025.
- Its Enterprise Value was $21.0 billion in Q3 2025, compared to $17.1 billion in Q2 2025 and $15.7 billion in Q1 2025.